Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
OptimizeRx Corp has a consensus price target of $24.82 based on the ratings of 11 analysts. The high is $66 issued by Roth Capital on May 5, 2022. The low is $11 issued by Barclays on August 12, 2024. The 3 most-recent analyst ratings were released by RBC Capital, Barclays, and JMP Securities on August 16, 2024, August 12, 2024, and June 24, 2024, respectively. With an average price target of $13.67 between RBC Capital, Barclays, and JMP Securities, there's an implied 73.43% upside for OptimizeRx Corp from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for OptimizeRx (NASDAQ:OPRX) was reported by RBC Capital on August 16, 2024. The analyst firm set a price target for $14.00 expecting OPRX to rise to within 12 months (a possible 77.66% upside). 12 analyst firms have reported ratings in the last year.
The latest analyst rating for OptimizeRx (NASDAQ:OPRX) was provided by RBC Capital, and OptimizeRx maintained their outperform rating.
There is no last upgrade for OptimizeRx
There is no last downgrade for OptimizeRx.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of OptimizeRx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for OptimizeRx was filed on August 16, 2024 so you should expect the next rating to be made available sometime around August 16, 2025.
While ratings are subjective and will change, the latest OptimizeRx (OPRX) rating was a maintained with a price target of $17.00 to $14.00. The current price OptimizeRx (OPRX) is trading at is $7.88, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.